MRNAModerna, Inc.
AI adoption · Q1 2026 earnings call
Health CarePiloting
2
extracted from this call
2 / 5
directional only
Not disclosed
no breakout in this call
AI was mentioned briefly twice by CEO Stephane Bancel in prepared remarks, both times in passing without quantification or operational detail. The first reference noted ongoing cross-enterprise AI projects aimed at reinventing work and driving personnel productivity. The second teased a Science Day presentation on June 25 where management plans to discuss how AI and robotics are being used to accelerate discovery of new mRNA drug modalities. No analyst asked about AI, and no financial metrics related to AI were disclosed.
Adopter
See full leaderboard →27/ 100
49
stage: piloting · max spec: 2
0
no quantified disclosure
35
1 scope
internal_use
2 AI mentions from this call.
Extracted verbatim from the MRNA Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.
- T2Prepared remarks· CEO· Internal use
“We'll continue to invest in AI with a number of cross enterprise projects to reinvent work with AI. We will, of course, continue to drive increased personnel productivity across the company.”
— Stéphane Bancel, MRNA earnings call - T2Prepared remarks· CEO· Internal use
“also how we're using AI and robotics to accelerate our ability to discover new technology to expand the use of mRNA to new drug modalities.”
— Stéphane Bancel, MRNA earnings call
What management wouldn’t quantify.
Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.
- No quantification of AI investment (capex, opex, or headcount) was provided despite CEO referencing 'a number of cross enterprise projects.'
- No specific AI use cases, tools, vendors, or platforms were named.
- No productivity metrics or outcomes attributed to AI were disclosed.
- Management deferred substantive AI disclosure to the Science Day on June 25, 2026.
- No analyst asked about AI on this call, so there was no opportunity for management to elaborate or be pressed for specifics.
Compare with peers.
Other companies in the same sector and at the same AI adoption stage.
Same GICS sector, all stages
Independent research, direct to your inbox.
Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.